Inventiva (NYSE:IVA) Shares Gap Up to $14.64

Inventiva S.A. (NYSE:IVA)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $14.64, but opened at $15.10. Inventiva shares last traded at $15.10, with a volume of 220 shares changing hands.

A number of research analysts recently issued reports on the company. Societe Generale reaffirmed a “sell” rating on shares of Inventiva in a report on Monday, March 15th. Roth Capital restated a “buy” rating on shares of Inventiva in a research report on Tuesday, May 4th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Inventiva currently has an average rating of “Buy” and an average price target of $27.33.

The stock’s 50-day simple moving average is $14.10.

A hedge fund recently bought a new stake in Inventiva stock. Credit Suisse AG acquired a new position in Inventiva S.A. (NYSE:IVA) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 29,336 shares of the company’s stock, valued at approximately $431,000. Credit Suisse AG owned 0.08% of Inventiva as of its most recent SEC filing.

About Inventiva (NYSE:IVA)

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH.

Read More: Shanghai Stock Exchange Composite Index

Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.